Dana V Ferraris

List of Publications by Citations

11 papers	500 citations	8 h-index	13 g-index
13 ext. papers	616 ext. citations	5.6 avg, IF	4.34 L-index

#	Paper	IF	Citations
11	Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. *Journal of Medicinal Chemistry*, **2010**, 53, 4561-84	8.3	267
10	The coronavirus macrodomain is required to prevent PARP-mediated inhibition of virus replication and enhancement of IFN expression. *PLoS Pathogens*, **2019**, 15, e1007756	7.6	93
9	Discovery of 6-Diazo-5-oxo-l-norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma. *Journal of Medicinal Chemistry*, **2016**, 59, 8621-33	8.3	53
8	Design, synthesis and evaluation of potent and selective inhibitors of mono-(ADP-ribosyl)transferases PARP10 and PARP14. *Bioorganic and Medicinal Chemistry Letters*, **2018**, 28, 2050-2054	2.9	24
7	Discovery of Orally Available Prodrugs of the Glutamate Carboxypeptidase II (GCPII) Inhibitor 2-Phosphonomethylpentanedioic Acid (2-PMPA). *Journal of Medicinal Chemistry*, **2016**, 59, 2810-9	8.3	19
6	Unprecedented Binding Mode of Hydroxamate-Based Inhibitors of Glutamate Carboxypeptidase II: Structural Characterization and Biological Activity. *Journal of Medicinal Chemistry*, **2016**, 59, 4539-50	8.3	11
5	Synthesis, characterization and antineoplastic activity of bis-aziridinyl dimeric naphthoquinone - A novel class of compounds with potent activity against acute myeloid leukemia cells. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 6-10	2.9	8
4	D-Amino acid oxidase inhibitors based on the 5-hydroxy-1,2,4-triazin-6(1H)-one scaffold. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 2088-91	2.9	8
3	Analysis of the Mechanisms of Action of Naphthoquinone-Based Anti-Acute Myeloid Leukemia Chemotherapeutics. *Molecules*, **2019**, 24,	4.8	7
2	Integrating DNA-encoded chemical libraries with virtual combinatorial library screening: Optimizing a PARP10 inhibitor. *Bioorganic and Medicinal Chemistry Letters*, **2020**, 30, 127464	2.9	5
1	Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020). *Expert Opinion on Therapeutic Patents*, **2021**, 31, 609-623	6.8	5